MILWAUKEE, Sept. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq:ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.
Read more at prnewswire.comShareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here